Meet the Team
Our team is composed of dedicated doctors and business leaders focusing on advancing the field of vitiligo to create a safe and effective treatment for all.
Sumeet Dagar
PhD, MBA
CEO
Sumeet is an accomplished senior executive in the biopharmaceutical industry with over 23 years of global cross-functional experience across the healthcare value chain, leading global business development, operations, product development, commercialization and successfully running business units in North America, EU and Asia.
Caroline Le Poole
PhD
CSO & Co-Founder
Caroline is a Professor of Dermatology, Microbiology and Immunology at the Northwestern Feinberg School of Medicine with decades of experience in Investigative Dermatology and Immunology research. Professor Le Poole has held numerous NIH grants focusing on various aspects of immunotherapy. Professor Le Poole earned her PhD at the University of Amsterdam. She is the lead inventor of the HSP70i based therapy.
Kettil Cedercreutz
MSME, PhD
Board Member & Co-Founder
Kettil holds extensive service as Professor, Associate Provost and Dean at the University of Cincinnati at the intersection of academia and industry. Kettil holds a MSc degree in Industrial Economics and Manufacturing Engineering from the top Engineering School in Finland. His PhD focuses on statistical analysis of assessment data. Kettil has a solid background in market-oriented development of products and services.
Paul Burton
JD, MBA
CFO & Board Member
Paul has 19 years of experience in corporate finance, running small businesses, and working for firms such as Citigroup Corporate & Investment Bank and GE Capital. Paul Burton is a serial entrepreneur, with a track record of retargeting drugs for the pharmaceutical market. His background includes serving as a U.S. Regular Army Commissioned Officer (Infantry, First Lieutenant) and currently serves as an Entrepreneur in Residence at Northwestern University. He is in charge of organizing fundraising campaigns for Temprian.
Modestus Obochi
PhD, MBA
Commercialization & Board Member
Modi is an accomplished executive with global diverse industry-leading experiences across pharmaceutical and biotechnology industries, including operational leadership and advisory roles with demonstrated successes in growing revenues, shareholder value, and managing global P&L in start-up, medium and large companies.
Mukesh Kumar
PhD, RAC
Regulatory Affairs
Mukesh has 25+ years of experience in regulatory affairs and quality assurance for the development and manufacture of pharmaceutical and biotech products. He has been involved in excess of 100 multi-national clinical trials, filing numerous submissions with the US Food and Drug Administration (FDA). Dr. Kumar authors a popular weekly newsletter on FDA-related issues subscribed by more than 100,000 readers worldwide.
John Nieland
PhD
Chief Innovation Officer
John has an in-depth background in immunology, biopharmaceuticals and clinical trials. In addition to his scientific experience, John is a founder of three biotech companies. As director of research at Medigene AG John was involved in the development of the AAV-HPV vaccine. He is the former vice president of preclinical research at Borean Pharma. John is the inventor on 15 patents, including several on the AAV vaccine platform. At Temprian John’s responsibilities include the development of the Temprian Therapeutics portfolio.
Pearl Grimes
MD
Clinical Advisor
Dr. Grimesis a globally recognized dermatologic expert and a leading international authority on vitiligo and pigmentation disorders. As Director of the Vitiligo and Pigmentation Institute of Southern California, she treats patients from all over the world who seek her expertise and extraordinary patient care.